Search clinical trials for: Programmed Cell Death 1 Ligand 1 (PDL 1, PD-L1)

Total 93379 results

Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Non-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)

Japan
AstraZeneca

Completed

Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient

Asthma

Spain
University Hospital, Montpellier

Completed

Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation (ImmunEO)

Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies

France
University of Colorado, Denver

Recruiting

Breaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes (BURST2D)

Pre-diabetes

United States
Fuzhou General Hospital

Unknown

DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma

Renal Cell Carcinoma

China
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

Hodgkin Lymphoma

United States, Brazil, Colombia, Czechia, France, Germany, Greece, Guatemala, Italy, Korea, Republic of, Mexico, Netherlands, Slovakia, South Africa, Spain, United Kingdom
Seoul National University Hospital

Unknown

Verify the Effectiveness rTMS Using MEG (rTMS)

Tinnitus

Korea, Republic of
Shanghai Zhongshan Hospital

Recruiting

Gut Microbiota and Cancer Immunotherapy Response

Non-Small Cell Lung Cancer

China
Baodong Qin

Unknown

Effect of Chemotherapy on TMB in NSCLC

Chemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 Inhibitor

China
Tan Tock Seng Hospital
National University Hospital, Singapore; Singapore General Hospital; Changi General...

Withdrawn

Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria (XDR-GNB)

Bacteremia | Ventilator-associated Pneumonia | Healthcare-associated Pneumonia

Singapore
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

Non-small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer

Locally Advanced Colorectal Carcinoma

China
Merck Sharp & Dohme LLC

Terminated

Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)

Neoplasms | Head and Neck Neoplasms | Colorectal Neoplasms

Australia, Hong Kong
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)

Carcinoma, Non-Small-Cell Lung

United States, Australia, Brazil, Chile, China, Costa Rica, Dominican Republic, Germany, Greece, Guatemala, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Spain, Turkey, Portugal, Romania, South Africa, Philippines, Ukr...
Mansoura University

Completed

Early Versus Late Cholecystectomy After Clearance of Common Bile Duct Stones (ERCP)

Gallbladder and Bile Duct Calculi
Novartis
Novartis Vaccines

Completed

Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup

Influenza

Poland
Merck Sharp & Dohme LLC

Completed

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

Head and Neck Squamous Cell Carcinoma
Guohui Li

Recruiting

Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients

PD-1 | Immune Related Adverse Events

China
Johns Hopkins University

Completed

Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder

Smoking | Smoking Cessation | Treatment Resistant Depression | MDD

United States
Shanghai Zhongshan Hospital

Not yet recruiting

A Risk Prediction Model of Postoperative Nausea and Vomiting in Patients With Liver Cancer

Liver Cancer | Nausea and Vomiting, Postoperative
Rigshospitalet, Denmark
Danish Cancer Society; Danish Breast Cancer Cooperative Group

Unknown

Chronic Pain After Operation for Breast Cancer

Pain Threshold

Denmark
University Hospital, Umeå

Recruiting

Multicenter Study for Diagnosis and Treatment of Perianal Abscesses

Perianal Abscess | Incontinence | Anal Fistulas

Sweden
UNICANCER
Fondation ARC

Active, not recruiting

Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists (CHECK'UP)

Melanoma | Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

France
UCB BIOSCIENCES GmbH

Completed

Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian Subjects

Healthy

Germany
UCB Pharma SA

Completed

Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations

Healthy

China
UCB Pharma

Completed

A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers

Human Volunteers

China
Merck Sharp & Dohme LLC

Terminated

Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)

Advanced Solid Tumors

France, Germany, Spain, United Kingdom
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom
Boston Children's Hospital
Boston University; National Institute of Diabetes and Digestive and Kidney...

Completed

Nutrition Study for School Age Children

Obesity

United States
Belén Retamal-Valdes

Unknown

Amoxicillin and Metronidazole During Periodontal Treatment (MOMENT)

Chronic Periodontitis

Brazil
UCB BIOSCIENCES GmbH

Completed

Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Single Dose Lacosamide in Subjects With Renal Impairment Compared to Healthy Subjects

Healthy | Renal Impairment

Germany
Instituto Nacional de Cancerologia de Mexico

Unknown

Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients

Non-Small Cell Lung Cancer

Mexico
NovoCure GmbH

Recruiting

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

Spain
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension

Prostatic Neoplasms

China
Novartis Pharmaceuticals

Completed

Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study. (MAXIMIZA)

Prophilaxis of Acute Rejection in Patients Receiving a Renal Allograft

Spain
Swedish University of Agricultural Sciences
Uppsala University

Completed

The Effect of Dietary Fibre and Plant Protein on Appetite and Metabolic Function

Appetite Regulation

Sweden
Ruijin Hospital

Recruiting

Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation (Cryo-InitialAF)

Arrhythmias, Cardiac | Atrial Fibrillation, Persistent

China
Duke University

Completed

Retisert and Cataract Surgery in Patients With Severe Uveitis

Posterior Uveitis | Intermediate Uveitis

United States
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

Hepatitis C Virus Infection

Japan
National Institute on Drug Abuse (NIDA)
University of Pennsylvania

Completed

Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1

Substance-Related Disorders | Opioid-Related Disorders

United States
CAR-T (Shanghai) Biotechnology Co., Ltd.

Unknown

Clinical Study of Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee Osteoarthritis

Knee Osteoarthritis

China
University of Michigan Rogel Cancer Center
American Society of Clinical Oncology

Completed

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

Breast Cancer | Arthralgia

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

Advanced or Metastatic Solid Tumors

United States, Canada, Israel, Netherlands
Merck Sharp & Dohme LLC

Recruiting

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Carcinoma, Non-Small-Cell Lung

Poland, United States, Hungary, Israel, Italy, Korea, Republic of, Spain
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

Squamous Cell Carcinoma of Head and Neck

Canada, United States, Argentina, Australia, Brazil
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Gastric Cancer | Gastroesophageal Junction Cancer

China
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) (LEAP-015)

Advanced/Metastatic Gastroesophageal Adenocarcinoma

China, Japan, Poland, Hong Kong, Korea, Republic of, Canada, United States, Argentina, Australia, Belgium, Chile, Colombia, Costa Rica, France, Germany, Guatemala, Ireland, Israel, Italy, Russian Federation, Spain, Taiwan, Turkey, United...
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Cervical Cancer

Japan, United States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Mexico, Peru, Russian Federation, Spain, Taiwan, Turkey, Ukraine
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

Melanoma

Spain, United States, Australia, France, Israel, Italy, South Africa, Switzerland
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Metastatic Hormone-Sensitive Prostate Cancer

Taiwan, Poland, United States, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Peru, Russian Federation, Spai... and more

3

Subscribe